Beatrix J.
- Country
- Germany
- Department
- Klinik für Gynäkologie und Geburtshilfe
Research Overview
- Phase III Randomized Controlled Trial of Abemaciclib Plus Endocrine Therapy Versus Endocrine Therapy in HR+/HER2- Early Breast Cancer with Intermediate to High Risk
- Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer
Data & Insights
Has run more than one trial at 46 of 131 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular focus on early-stage disease management.
- Endocrine Therapy Applications
- Targeted Treatment Approaches
- Early-Stage Disease Management
Their research encompasses innovative therapeutic combinations including targeted therapies with endocrine treatment.
Personalized Medicine
The investigator focuses on developing dynamic marker-adjusted personalized therapy approaches for breast cancer treatment optimization.
- Biomarker-Driven Treatment Selection
- Risk-Adapted Therapy Strategies
- Personalized Treatment Protocols
Their work emphasizes tailoring treatments based on individual patient characteristics and disease markers.
Treatment Outcomes
The investigator evaluates therapeutic effectiveness through measurement of invasive disease-free survival and long-term treatment outcomes.
- Survival Rate Assessment
- Disease Recurrence Monitoring
- Treatment Response Evaluation
Their research aims to improve survival outcomes in breast cancer patients through optimized treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.